# Clinical VOLUME 30 NUMBER 3 SUMMER 2012 Diabetes Diabetes Merican Diabetes Association.

#### Practical Information for Primary Care

#### *editorial* "Diabetic" and "Noncompliant Diabetic": Terms That Need to Disappear KYLE R. PETERS, PHARMD

#### feature articles

- Commentary: Exenatide QW: A New Treatment Option for Type 2 Diabetes Offering Ease of Use, Improved Efficacy, and Reduced Side Effects CHARLES F. SHAEFER, JR., MD
- 5 Once-Weekly Glucose-Lowering Therapy for Type 2 Diabetes susan larue, rd, cde, mary beth deyoung, phd, amy blickensderfer, pharmd, and steve chen, md
- Diabetes Symptoms and Distress in ACCORD Trial Participants: Relationship to Baseline Clinical Variables MARK D. SULLIVAN, MD, PHD, GREGORY EVANS, MA, ROGER ANDERSON, PHD, PATRICK O'CONNOR, MD, MPH, DENNIS W. RAISCH, PHD, DEBRA L. SIMMONS, MD, MS, AND K.M. VENKAT NARAYAN, MD, MBA

## **10** bridges to excellence

N.C. Diabetes Education Recognition Program: ADA Recognition for a Combined Program at Local Health Departments and Community Health Centers in North Carolina

JOANNE RINKER, MS, RD, CDE, LDN, AND MARTI WOLF, RN, MPH

### **5** translating research to practice

Another Telescope for Examining Statins: the SATURN Trial reviewed by Rikesh Patel, MD, and ROBERT J. CHILTON, DO, FACC

#### case studies

Challenges of Type 2 Diabetes in Patients With Alcohol Dependence dalal alromaini, md, judith zielke, rn, and arti bhan, md

Liraglutide: 52 Weeks and 59 lb Later Kyle R. PETERS, PHARMD, BC-ADM, CDE

# 26 practical pointers

Matching Patients to Devices: Diabetes Products Are Not One-Size-Fits-All GARY SCHEINER, MS, CDE

### diabetes advocacy

The Disparate Impact of Diabetes on Racial/Ethnic Minority Populations Edward A. CHOW, MD, HENRY FOSTER, MD, VICTOR GONZALEZ, MD, AND LASHAWN MCIVER, MD, MPH